These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 11907807)

  • 41. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
    Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections.
    Burger PC; Minn AY; Smith JS; Borell TJ; Jedlicka AE; Huntley BK; Goldthwaite PT; Jenkins RB; Feuerstein BG
    Mod Pathol; 2001 Sep; 14(9):842-53. PubMed ID: 11557779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
    Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reclassification of oligoastrocytomas by loss of heterozygosity studies.
    Eoli M; Bissola L; Bruzzone MG; Pollo B; Maccagnano C; De Simone T; Valletta L; Silvani A; Bianchessi D; Broggi G; Boiardi A; Finocchiaro G
    Int J Cancer; 2006 Jul; 119(1):84-90. PubMed ID: 16432842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.
    Pasini A; Iorio P; Bianchi E; Cerasoli S; Cremonini AM; Faedi M; Guarnieri C; Guiducci G; Riccioni L; Molinari C; Rengucci C; Calistri D; Giordano E
    Oncol Rep; 2012 Dec; 28(6):2271-7. PubMed ID: 22992787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets.
    Mueller W; Hartmann C; Hoffmann A; Lanksch W; Kiwit J; Tonn J; Veelken J; Schramm J; Weller M; Wiestler OD; Louis DN; von Deimling A
    Am J Pathol; 2002 Jul; 161(1):313-9. PubMed ID: 12107116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype.
    Jenkinson MD; Smith TS; Brodbelt AR; Joyce KA; Warnke PC; Walker C
    J Magn Reson Imaging; 2007 Dec; 26(6):1405-12. PubMed ID: 17968881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.
    von Deimling A; Louis DN; von Ammon K; Petersen I; Wiestler OD; Seizinger BR
    Cancer Res; 1992 Aug; 52(15):4277-9. PubMed ID: 1353411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
    Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
    Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
    Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG
    Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas.
    Yang P; Kollmeyer TM; Buckner K; Bamlet W; Ballman KV; Jenkins RB
    Cancer; 2005 Jun; 103(11):2363-72. PubMed ID: 15834925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
    Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
    PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
    Griffin CA; Burger P; Morsberger L; Yonescu R; Swierczynski S; Weingart JD; Murphy KM
    J Neuropathol Exp Neurol; 2006 Oct; 65(10):988-94. PubMed ID: 17021403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.
    Horbinski C; Nikiforova MN; Hobbs J; Bortoluzzi S; Cieply K; Dacic S; Hamilton RL
    J Neuropathol Exp Neurol; 2012 Jan; 71(1):73-82. PubMed ID: 22157622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.